Standard First-Line Chemotherapy

PreclinicalSmall molecule

Standard First-Line Chemotherapy is one of 43 small molecule programs targeting Pancreatic Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

1 10

Cyclophosphamid

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Pancreatic Cancer

NCT07407231

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)

Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07407231·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard First-Line Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard First-Line Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard First-Line Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Oncology Ljubljana company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Oncology Ljubljana

Standard First-Line Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News